News

myTomorrows Secures Major Funding to Enhance Patient Therapy Access

myTomorrows Secures Major Funding to Enhance Patient Therapy Access

Transforming Patient Access to Innovative Therapies

In a significant move to enhance the accessibility of innovative treatments, myTomorrows has successfully raised $29 million in financing. This funding, backed by Avego, aims to expand myTomorrows’ global footprint and accelerate the advancement of AI innovations in healthcare. The investment will also strengthen partnerships within the industry, facilitating a broader reach in patient care.

MyTomorrows’ Commitment to Bridging Treatment Gaps

Currently, more than 300 million patients worldwide are confronted with conditions that lack approved treatment options. Moreover, there are over 10,000 therapies either in development or pending approval. myTomorrows thrives on this pressing healthcare challenge by connecting patients with pre-approval treatments, including opportunities for clinical trials and expanded access programs (EAPs).

The recent financial influx is set to fast-track myTomorrows’ international growth, further enhancing its AI-driven platform designed to connect physicians, patients, trial sites, and BioPharma partners seamlessly. This platform strives to optimize accessibility and insights into treatment options, while also fostering collaborations with industry partners aimed at reducing clinical development timelines.

Insights from the Leadership

Michel van Harten, the CEO of myTomorrows, expressed the transformative potential of this investment: "This marks a pivotal step in our journey to ensure that every patient has a fair opportunity to access tomorrow's therapies, regardless of location." He highlighted that Avego's extensive life sciences expertise, especially within the BioPharma sector, is crucial for scaling their platform and amplifying their global impact.

James Flexner, Managing Partner of Avego, also acknowledged the importance of this collaboration, stating, "We support myTomorrows in its mission to revolutionize patient access to therapies in development. Their unique position will help eliminate barriers for both patients and providers while reinforcing their role as a vital partner to BioPharma companies."

Innovative Solutions for Global Patient Needs

Founded in 2012, myTomorrows was born out of a vision to create better connections between patients and promising therapies. With this latest funding, the company is ready to enter a new phase characterized by rapid growth and significant global impact.

The company has introduced the world’s most comprehensive AI-powered platform for pre-approval treatments, successfully aiding over 16,900 patients in accessing therapies across more than 133 countries. MyTomorrows offers essential navigation services, treatment matching, and improved access to clinical trials and EAPs, proving its commitment to enhancing patient experience.

For BioPharma partnerships, myTomorrows provides strategic solutions for clinical trial recruitment and expanded access while offering real-world data collection capabilities. Additionally, trial sites benefit from a cohesive referral management system that not only elevates trial visibility but also ensures up-to-date status information.

A Vision for the Future of Treatment Access

As the primary gateway for pre-approval therapies, myTomorrows is laying the groundwork for a new era in treatment access, characterized by AI-enhanced transformation, adaptive regulations, and informed patients actively engaged in their healthcare.

Through a robust integration within global healthcare systems, their platform ensures that emerging therapies reach the patients who need them most, precisely when they are needed.

About myTomorrows

myTomorrows stands out as a pioneering global HealthTech company dedicated to connecting patients, physicians, trial sites, and BioPharma partners. This endeavor fosters faster and improved access to pre-approval treatments. By harnessing a centralized platform powered by AI-driven insights and human expertise, myTomorrows tackles some of the significant barriers patients face in accessing healthcare.

Operating from Amsterdam with a branch in New York City, myTomorrows has proudly supported over 16,900 patients and 2,800 physicians across more than 340 sites in over 133 nations.

Frequently Asked Questions

What does myTomorrows focus on?

myTomorrows connects patients with innovative pre-approval treatments, enhancing access to clinical trials and therapies awaiting approval.

What is the significance of the recent funding?

The $29 million funding from Avego will enable myTomorrows to expand its global reach and enhance its AI-driven platform for improved patient access.

How does myTomorrows support patients in need?

MyTomorrows provides expert navigation services, treatment matching, and simplifies access to clinical trials and expanded access programs for patients.

How many patients has myTomorrows helped?

To date, myTomorrows has assisted over 16,900 patients across more than 133 countries worldwide.

What industry partnerships does myTomorrows foster?

MyTomorrows collaborates with BioPharma companies, providing solutions for clinical trial recruitment and real-world data collection to expedite the therapeutic landscape.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 142

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 54

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 156

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 114

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 24

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 121

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Eagle Pharmaceuticals Board Advances Rights Plan for Shareholders

Updated Category News Views 231

Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...

Continue Reading
How Trump's Immigration Policies Could Impact US Growth

Updated Category News Views 338

Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...

Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Ahead

Updated Category News Views 142

Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...

Continue Reading
Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care

Updated Category News Views 90

Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...

Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update

Updated Category News Views 282

Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...

Continue Reading